Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jukka Westerbacka

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
The Journal of Clinical Endocrinology and Metabolism|October 15, 2003
Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liverJukka Westerbacka, Hannele Yki-Järvinen, Satu Vehkavaara, et al.
Antiviral Therapy|August 20, 2003
Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled studyJussi Sutinen, Anna-Maija Häkkinen, Jukka Westerbacka, et al.
AIDS (London, England)|November 1, 2002
Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophyJussi Sutinen, Anna-Maija Häkkinen, Jukka Westerbacka, et al.
American Journal of Physiology. Endocrinology and Metabolism|December 9, 2004
Acquired obesity is associated with increased liver fat, intra-abdominal fat, and insulin resistance in young adult monozygotic twinsKirsi Hannele Pietiläinen, Aila Rissanen, Jaakko Kaprio, et al.
Diabetes, Obesity & Metabolism|December 23, 2017
Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulinFang Liz Zhou, Fen Ye, Paulos Berhanu, et al.
Bioinformatics (Oxford, England)|July 25, 2007
Exploring the lipoprotein composition using Bayesian regression on serum lipidomic profilesMarko Sysi-Aho, Aki Vehtari, Vidya R Velagapudi, et al.
Diabetes, Obesity & Metabolism|October 20, 2022
Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trialTadej Battelino, Thomas Danne, Steve V Edelman, et al.
Diabetes, Obesity & Metabolism|June 26, 2018
Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort studySean D Sullivan, Timothy S Bailey, Ronan Roussel, et al.
Radiology|July 27, 2010
Nonalcoholic fatty liver disease: detection of elevated nicotinamide adenine dinucleotide phosphate with in vivo 3.0-T 31P MR spectroscopy with proton decouplingKsenia Sevastianova, Antti Hakkarainen, Anna Kotronen, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 11, 2005
Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemiaMartin Adiels, Jan Borén, Muriel J Caslake, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
The Journal of Clinical Endocrinology and Metabolism|October 15, 2003
Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liverJukka Westerbacka, Hannele Yki-Järvinen, Satu Vehkavaara, et al.
Antiviral Therapy|August 20, 2003
Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled studyJussi Sutinen, Anna-Maija Häkkinen, Jukka Westerbacka, et al.
AIDS (London, England)|November 1, 2002
Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophyJussi Sutinen, Anna-Maija Häkkinen, Jukka Westerbacka, et al.
American Journal of Physiology. Endocrinology and Metabolism|December 9, 2004
Acquired obesity is associated with increased liver fat, intra-abdominal fat, and insulin resistance in young adult monozygotic twinsKirsi Hannele Pietiläinen, Aila Rissanen, Jaakko Kaprio, et al.
Diabetes, Obesity & Metabolism|December 23, 2017
Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulinFang Liz Zhou, Fen Ye, Paulos Berhanu, et al.
Bioinformatics (Oxford, England)|July 25, 2007
Exploring the lipoprotein composition using Bayesian regression on serum lipidomic profilesMarko Sysi-Aho, Aki Vehtari, Vidya R Velagapudi, et al.
Diabetes, Obesity & Metabolism|October 20, 2022
Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trialTadej Battelino, Thomas Danne, Steve V Edelman, et al.
Diabetes, Obesity & Metabolism|June 26, 2018
Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort studySean D Sullivan, Timothy S Bailey, Ronan Roussel, et al.
Radiology|July 27, 2010
Nonalcoholic fatty liver disease: detection of elevated nicotinamide adenine dinucleotide phosphate with in vivo 3.0-T 31P MR spectroscopy with proton decouplingKsenia Sevastianova, Antti Hakkarainen, Anna Kotronen, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 11, 2005
Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemiaMartin Adiels, Jan Borén, Muriel J Caslake, et al.
Pageof 6